RU2672569C2 - Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата - Google Patents

Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата Download PDF

Info

Publication number
RU2672569C2
RU2672569C2 RU2017109818A RU2017109818A RU2672569C2 RU 2672569 C2 RU2672569 C2 RU 2672569C2 RU 2017109818 A RU2017109818 A RU 2017109818A RU 2017109818 A RU2017109818 A RU 2017109818A RU 2672569 C2 RU2672569 C2 RU 2672569C2
Authority
RU
Russia
Prior art keywords
compound
formula
disease
disorders
pxt002331
Prior art date
Application number
RU2017109818A
Other languages
English (en)
Russian (ru)
Other versions
RU2017109818A (ru
RU2017109818A3 (cg-RX-API-DMAC7.html
Inventor
Дельфин ШАРВЕН
Батист МАНТО
Венсан Помель
Франсуа КОНКЕ
Original Assignee
Прекстон Терапьютикс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прекстон Терапьютикс Са filed Critical Прекстон Терапьютикс Са
Publication of RU2017109818A publication Critical patent/RU2017109818A/ru
Publication of RU2017109818A3 publication Critical patent/RU2017109818A3/ru
Application granted granted Critical
Publication of RU2672569C2 publication Critical patent/RU2672569C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017109818A 2014-08-27 2015-08-27 Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата RU2672569C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182468 2014-08-27
EP14182468.0 2014-08-27
PCT/EP2015/069601 WO2016030444A1 (en) 2014-08-27 2015-08-27 Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

Publications (3)

Publication Number Publication Date
RU2017109818A RU2017109818A (ru) 2018-10-01
RU2017109818A3 RU2017109818A3 (cg-RX-API-DMAC7.html) 2018-10-01
RU2672569C2 true RU2672569C2 (ru) 2018-11-16

Family

ID=51421865

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017109818A RU2672569C2 (ru) 2014-08-27 2015-08-27 Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата

Country Status (26)

Country Link
US (3) US10017521B2 (cg-RX-API-DMAC7.html)
EP (3) EP3186257B1 (cg-RX-API-DMAC7.html)
JP (1) JP6430015B2 (cg-RX-API-DMAC7.html)
KR (1) KR101870589B1 (cg-RX-API-DMAC7.html)
CN (2) CN110343118A (cg-RX-API-DMAC7.html)
AU (1) AU2015308438B2 (cg-RX-API-DMAC7.html)
CA (1) CA2956191C (cg-RX-API-DMAC7.html)
CY (1) CY1121352T1 (cg-RX-API-DMAC7.html)
DK (1) DK3186257T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714073T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190343T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041941T2 (cg-RX-API-DMAC7.html)
IL (1) IL250287B (cg-RX-API-DMAC7.html)
LT (1) LT3186257T (cg-RX-API-DMAC7.html)
MA (3) MA52702A (cg-RX-API-DMAC7.html)
ME (1) ME03339B (cg-RX-API-DMAC7.html)
MX (1) MX369643B (cg-RX-API-DMAC7.html)
NZ (1) NZ728853A (cg-RX-API-DMAC7.html)
PL (1) PL3186257T3 (cg-RX-API-DMAC7.html)
PT (1) PT3186257T (cg-RX-API-DMAC7.html)
RS (1) RS58592B1 (cg-RX-API-DMAC7.html)
RU (1) RU2672569C2 (cg-RX-API-DMAC7.html)
SI (1) SI3186257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900152T1 (cg-RX-API-DMAC7.html)
TR (1) TR201903332T4 (cg-RX-API-DMAC7.html)
WO (1) WO2016030444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3186257B1 (en) 2014-08-27 2019-02-06 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
RS59651B1 (sr) 2015-08-27 2020-01-31 Prexton Therapeutics Sa Derivat hromonoksima koji prodire u mozak u svrhu terapije diskinezije uzrokovane levodopom
MX2021000841A (es) 2018-07-26 2021-03-26 Domain Therapeutics Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051478A1 (en) * 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
RU2557059C2 (ru) * 2009-12-04 2015-07-20 Суновион Фармасьютикалз, Инк. Полициклические соединения и способы их применения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
WO2007011701A1 (en) 2005-07-15 2007-01-25 Transform Pharmaceuticals, Inc. Novel hydrochloride salts of levodopa
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
WO2013107862A1 (en) * 2012-01-18 2013-07-25 Addex Pharma S.A. NOVEL 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
EP3186257B1 (en) * 2014-08-27 2019-02-06 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
RS59651B1 (sr) 2015-08-27 2020-01-31 Prexton Therapeutics Sa Derivat hromonoksima koji prodire u mozak u svrhu terapije diskinezije uzrokovane levodopom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051478A1 (en) * 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
RU2557059C2 (ru) * 2009-12-04 2015-07-20 Суновион Фармасьютикалз, Инк. Полициклические соединения и способы их применения

Also Published As

Publication number Publication date
KR20170042624A (ko) 2017-04-19
MA48048A (fr) 2020-02-12
TR201903332T4 (tr) 2019-03-21
LT3186257T (lt) 2019-04-25
AU2015308438B2 (en) 2018-12-13
MX369643B (es) 2019-11-15
EP3502115A1 (en) 2019-06-26
HRP20190343T1 (hr) 2019-05-31
MA52702A (fr) 2021-03-31
EP3186257B1 (en) 2019-02-06
ME03339B (me) 2019-10-20
US10442818B2 (en) 2019-10-15
CA2956191C (en) 2020-01-28
EP3186257A1 (en) 2017-07-05
US20180291034A1 (en) 2018-10-11
HUE041941T2 (hu) 2019-06-28
PL3186257T3 (pl) 2019-07-31
IL250287A0 (en) 2017-03-30
CY1121352T1 (el) 2020-05-29
AU2015308438A1 (en) 2017-03-02
RS58592B1 (sr) 2019-05-31
CN106715444A (zh) 2017-05-24
CN110343118A (zh) 2019-10-18
PT3186257T (pt) 2019-03-27
EP3696183A1 (en) 2020-08-19
US20170253613A1 (en) 2017-09-07
JP6430015B2 (ja) 2018-11-28
MA40530A (fr) 2017-07-05
DK3186257T3 (en) 2019-04-01
US10017521B2 (en) 2018-07-10
CN106715444B (zh) 2019-07-12
JP2017525776A (ja) 2017-09-07
WO2016030444A1 (en) 2016-03-03
MX2017002429A (es) 2017-08-02
RU2017109818A (ru) 2018-10-01
NZ728853A (en) 2018-04-27
IL250287B (en) 2020-02-27
CA2956191A1 (en) 2016-03-03
US20200024285A1 (en) 2020-01-23
RU2017109818A3 (cg-RX-API-DMAC7.html) 2018-10-01
KR101870589B1 (ko) 2018-06-25
SMT201900152T1 (it) 2019-05-10
SI3186257T1 (sl) 2019-07-31
ES2714073T3 (es) 2019-05-27

Similar Documents

Publication Publication Date Title
KR101991327B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
US11008323B2 (en) Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
EA035016B1 (ru) Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
JP6517833B2 (ja) 神経変性疾患の処置に有用なウィザノライド
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
JP6751161B2 (ja) フッ素含有トリアゾロピリジン系化合物、その製造方法、医薬組成物及び用途
HK40010218A (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HK1233257B (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HK1233257A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
US11472832B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
Gao The development and evaluation of multi-target-directed ligands as cholinergic and amyloid β aggregation inhibitors for Alzheimer's disease
KR20070009735A (ko) 비전형적 항정신병제 활성을 갖는피롤로[2,1-ｂ]벤조티아제핀의 탈알킬화 유도체

Legal Events

Date Code Title Description
HE4A Change of address of a patent owner

Effective date: 20190619